Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Investment
    • PE, VC investments in...

    PE, VC investments in April touch USD 2.4 billion on large deals: EY

    Written by Ruby Khatun Khatun Published On 2018-05-20T09:45:20+05:30  |  Updated On 20 May 2018 9:45 AM IST
    PE, VC investments in April touch USD 2.4 billion on large deals: EY




    New Delhi: Private equity and venture capital investments in April were up 23 percent at USD 2.4 billion, backed by large deals in sectors like e-commerce and life sciences, says an EY report.

    According to EY, there were 69 PE/VC deals in April worth USD 2,370.09 million, while the corresponding month of 2017 had registered 66 such deals worth USD 1,920.32 million.

    "PE/VC deal activity in India continues to gather steam and become more robust. Both investments, as well as exits, are on an upward trend," said Vivek Soni, Partner, and Leader for Private Equity Advisory, EY.

    Exits also recorded a significant growth of 47 percent in terms of value during the same period, primarily on account of a single large exit by Actis worth USD 692 million.

    Soni said the recently announced majority acquisition of Flipkart by Walmart is expected to re-rate the Indian startup sector.

    "We believe it will inject new found enthusiasm and energy into the early to mid-stage investing eco-system and inspire many more entrepreneurs," he said.

    The next 4-5 years are expected to be the golden age for the Indian PE/VC sector, provided there is stability in the political as well as policy front, he said.

    The largest investment in April 2018 saw Softbank invest USD 400 million for a 21 percent stake in Paytm Mall.

    This was followed by couple of deals in the life sciences sector - USD 350 million investment in Mankind Pharma by ChrysCapital GIC and CPPIB for a 10 percent stake, and Apax Partner's USD 350 million acquisition of Healthium Medtech, a maker of the surgical equipment.




    AcquisitionChrysCapitale-commerceEYFlipkartInvestmentslife sciencesMankind PharmaPEPrivate equitySoftBanksurgical equipmentVCVenture capitalVivek Soni
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok